



Symptomatic SARS-CoV-2 infections after full schedule BNT162b2 vaccination in seropositive healthcare workers: a case series from a single institution

Andreina Baj, Federica Novazzi, Angelo Genoni, Francesca Drago Ferrante, Stefano Taborelli, Beatrice Pini, Michele Partenope, Marilena Valli, Daniela Dalla Gasperina, Riccardo Capuano, Martina Prestia, Pietro Giorgio Spezia, Lorenzo Azzi, Daniele Focosi & Fabrizio Maggi

To cite this article: Andreina Baj, Federica Novazzi, Angelo Genoni, Francesca Drago Ferrante, Stefano Taborelli, Beatrice Pini, Michele Partenope, Marilena Valli, Daniela Dalla Gasperina, Riccardo Capuano, Martina Prestia, Pietro Giorgio Spezia, Lorenzo Azzi, Daniele Focosi & Fabrizio Maggi (2021) Symptomatic SARS-CoV-2 infections after full schedule BNT162b2 vaccination in seropositive healthcare workers: a case series from a single institution, *Emerging Microbes & Infections*, 10:1, 1254-1256, DOI: [10.1080/22221751.2021.1942230](https://doi.org/10.1080/22221751.2021.1942230)

To link to this article: <https://doi.org/10.1080/22221751.2021.1942230>



© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.



Published online: 22 Jun 2021.



[Submit your article to this journal](#)



Article views: 3990



[View related articles](#)



[View Crossmark data](#)

Symptomatic SARS-CoV-2 infections after full schedule BNT162b2 vaccination in seropositive healthcare workers: a case series from a single institution

Andreina Baj^{1a}, Federica Novazzi^{2b}, Angelo Genoni^{3c}, Francesca Drago Ferrante^{4b}, Stefano Taborelli^{4d}, Beatrice Pini^{5e}, Michele Partenope^{5e}, Marilena Valli^{5e}, Daniela Dalla Gasperina^{6a}, Riccardo Capuano^{7b}, Martina Prestia^{8b}, Pietro Giorgio Spezia^{9f}, Lorenzo Azzi^{9g}, Daniele Focosi^{9h} and Fabrizio Maggi^{9a,b}

^aDepartment of Medicine and Surgery, University of Insubria, Varese, Italy; ^bLaboratory of Microbiology, ASST dei Sette Laghi, Varese, Italy; ^cDepartment of Biotechnology and Life Sciences, University of Insubria, Varese, Italy; ^dUnit of Occupational Medicine, ASST dei Sette Laghi, Varese, Italy; ^eClinical Pathology Unit, St. Anna Hospital, Como, Italy; ^fDepartment of Translational Research, University of Pisa, Pisa, Italy; ^gUnit of Oral Medicine and Pathology, ASST dei Sette Laghi, Varese, Italy; ^hNorth-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy

ABSTRACT

We report 11 cases of SARS-CoV-2 infection in healthcare workers (HCW) *naïve* for COVID-19 and seropositive after the second dose of the BNT162b2 mRNA vaccine. Based on voluntary-based surveillance, they tested positive for different strains of SARS-CoV-2, as Spike gene sequencing showed. Five of them reported mild symptoms. Given the risk for SARS-CoV-2 introduction from asymptomatic vaccinees, this case series suggests the need to continue nasopharyngeal screening programmes.

ARTICLE HISTORY Received 8 April 2021; Revised 8 June 2021; Accepted 8 June 2021

KEYWORDS COVID19; SARS-CoV-2; vaccine; BNT162b2; variants of interest

Dear Editor, the immune response to the COVID-19 vaccine is typically established by measuring anti-SARS-CoV-2 Spike or anti-RBD IgG in serum, even if no information about IgA levels in respiratory secretions or saliva is available. Playing a pivotal role to prevent SARS-CoV-2 infection and transmission, this has obvious implications for the final reach of herd immunity.

In Italy and many European countries, vaccination campaigns have been started in December 2020 with the BNT162b2 mRNA vaccine Comirnaty® (Pfizer/BioNtech), prioritizing healthcare workers (HCW). The susceptibility of vaccinated HCW to active, albeit asymptomatic, infection is of high interest given the risk of transmitting the virus to frail hospitalized patients. Additionally, the asymptomatic status in the vaccinated HCW could delay recognition of the index case, favouring nosocomial outbreaks.

We report here 11 HCW (mean age: 50±10 years, 3 male and 8 female) who tested positive for SARS-CoV-2 (m2000, Abbott Molecular, Des Plaines, IL), with a mean cycle threshold (Ct) of 19 (range Ct: 6–26) in nasopharyngeal swabs (NPS) after a variable period from the second dose of vaccine (mean days: 43±10).

They were part of voluntary-based surveillance, according to the guidelines of the Italian National Institute of Health and Ministry of Health and Local Ethical Committee (protocol n° 165/2020). All of them were *naïve* to COVID-19 and had successfully mounted anti-Spike serum IgG (LIAISON® SARS-CoV-2 S1/S2 IgG, DiaSorin, Saluggia, Italy) after full schedule vaccination, with a mean antibody titer of 214±99 arbitrary units (AU) for ml. While most cases were asymptomatic for the entire time between the first positive and the first negative NPS, 5 reported fever and arthralgia. Among them, cases #9 and #11 are notable because of positivity in rectal swab. Given the ECDC and Italian Ministry of Health recommendation to sequence SARS-CoV-2 isolated from vaccinees to detect immune-escaping variants of concern [1], we sequenced the entire Spike gene in all 11 cases. Sequences were deposited on GenBank and characterized using NextClade (<https://clades.nextstrain.org/>), showing the synchronous circulation of different SARS-CoV-2 strains in the Lombardy region. Table 1 summarized the laboratory findings in these cases.

Nevertheless the documented efficacy of BNT162b2 mRNA vaccine (7), at least one case of

CONTACT Andreina Baj  andreina.baj@uninsubria.it  Department of Medicine and Surgery, University of Insubria, Varese, Italy

© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Table 1. Summary of laboratory findings in the 11 vaccinated HCW.

#	Gender/ Age (yrs)	From 2nd dose to positive NPS (days)	From 1st positive to 1st negative NPS (days)	Symptoms	SARS CoV-2 RNA in rectal swab/saliva	Anti-S1/S2		Spike protein (aa substitutions)	Variant	GenBank ID
						rtPCR Ct	IgG (AU/ml)			
1	F/61	30	1	None	NA	24	174	R346S, L452R, N501Y, A570D D614G, Q677H P681H, A899S del69-70, del144 N501Y, A570D L452R, N501Y, A570D	UK (20/501Y.V1 or B.1.1.7)	MW826653
2	M/37	34	1	None	NA	26	209	N501Y, A570D	UK (Y380Y+ V433V)	MW826670
3	F/61	52	NA	fever, arthralgia, rhinitis	NA	20	205	L452R, N501Y, A570D	UK + L452R	MW834428
4	M/60	23	13	None	NA	25	294	N501Y, A570D D614G, Q677H P681H, A899S S982A, del69-70, del144 N501Y, A570D	UK (20/501Y.V1 or B.1.1.7)	MW826840
5	F/55	57	NA	fever, arthralgia, rhinitis	NA	22	123	N501Y, A570D	UK (20/501Y.V1 or B.1.1.7)	MW834320
6	F/50	51	15	fever, arthralgia, rhinitis	NA	16	131	N501Y, A570D, D614G, P681H, T716I, S982A, D1118H, del69-70, del144 None	UK (20/501Y.V1 or B.1.1.7)	MW827173
7	F/28	44	12	rhinitis, anosmia, cough	Negative/ Negative	NA	397	None	-	MW815132
8	F/48	47	2	None	NA	16	185	None	-	MW827227
9	F/56	48	15	fever, arthralgia, rhinitis	Positive (Ct 27)/ Positive (Ct 15)	6	110	N501Y, A570D	UK (20/501Y.V1 or B.1.1.7)	MW827231
10	M/44	48	4	none	NA	NA	158	N501Y, A570D	UK (20/501Y.V1 or B.1.1.7)	MW827585
11	F/55	48	4	fever, arthralgia, rhinitis	Positive (Ct 24)/ Positive (Ct 33)	24	378	N501Y, A570D	UK (20/501Y.V1 or B.1.1.7)	MW827588

asymptomatic infection in a vaccinated HCW has been recently reported [2], but since the biological samples were limited to NPS, it could not be concluded whether the infection had been contained on the nasopharynx or not. Our series is the first to demonstrate that in fully vaccinated HCW, SARS-CoV-2 is not only able to colonize the nasopharynx, but also to infect cells in distant tissues and give clinical symptoms. No case of nosocomial transmission from the HCW described in this series to inpatients has been documented to date, even if the low Ct found is a suggestion of a viable and transmissible virus.

While we cannot conclude whether the detected viral RNA was immunocomplexed or not, it is well known that sterilizing immunity against respiratory viruses largely depends on neutralizing IgA levels in secretions. Unfortunately, the intramuscular route of the currently approved vaccines only induces low-level IgA in secretions in a minority of recipients [3–5].

Disclosure statement

No potential conflict of interest was reported by the author(s).

ORCID

Andreina Baj  <http://orcid.org/0000-0003-0088-2712>

References

- [1] European Centre for Disease Prevention and Control. Sequencing of SARS-CoV-2: first update. 18 January 2021. ECDC: Stockholm; 2021.
- [2] Schiavone M, Gasperetti A, Mitacchione G, et al. Response to: COVID-19 re-infection. Vaccinated individuals as a potential source of transmission. *Eur J Clin Invest.* 2021; e13544. DOI:10.1111/eci.13544
- [3] Ketas TJ, Chaturbhuj D, Cruz-Portillo VM, et al. Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva. *bioRxiv* [Preprint]. 2021. DOI:10.1101/2021.03.11.434841
- [4] Lixenfeld AS, Künsting I, Martin EL, et al. The BioNTech / Pfizer vaccine BNT162b2 induces class-switched SARS-CoV-2-specific plasma cells and potential memory B cells as well as IgG and IgA serum and IgG saliva antibodies upon the first immunization. *medRxiv.* 2021. DOI:10.1101/2021.03.10.21252001
- [5] European Centre for Disease Prevention and Control. Risk of SARS-CoV-2 transmission from newly-infected individuals with documented previous infection or vaccination. 29 March 2021. ECDC: Stockholm, 2021.